RSS Newsfeeds

See all RSS Newsfeeds

Jul 17, 2017 9:20 AM ET

Global Clostridium Difficile Treatment Market to Grow at a CAGR of 5.14% During 2017-2021: Key Vendors are Actelion Pharmaceuticals, Merck, Pfizer & Summit Therapeutics

iCrowdNewswire - Jul 17, 2017

The “Global Clostridium Difficile Treatment Market 2017-2021” report has been added to Research and Markets’ offering.

The global clostridium defficile treatment market to grow at a CAGR of 5.14% during the period 2017-2021.

The report, Global Clostridium Defficile Treatment Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the Key vendors operating in this market.

One trend in the market is special designation. Special designations such as Fast Track and Qualified Infectious Disease Product (QIDP), which are provided by the FDA, will encourage vendors to launch new products. These designations are beneficial for the market as they will enable the quick completion of the clinical trial process.

According to the report, one driver in the market is rise in aging population. As people age, their immune systems deteriorate. People above the age of 60 may experience several medical complications. Aging plays a significant role in the manifestation of CDI. Research studies estimate that people above the age of 60 are susceptible to CDI, with the median age of diagnosis being 70. The rise in the aging population will increase the number of people affected by CDI.

Key vendors

– Actelion Pharmaceuticals
– Merck
– Pfizer
– Summit Therapeutics

Other prominent vendors

– Astellas Pharma
– Da Volterra
– Immuron
– MGB Biopharma
– Novartis
– Otsuka Pharmaceutical
– Others

Key Topics Covered:

PART 01: Executive summary

PART 02: Scope of the report

PART 03: Research Methodology

PART 04: Introduction

PART 05: Pipeline landscape

PART 06: Market landscape

PART 07: Market segmentation by drug category

PART 08: Geographical segmentation

PART 09: Decision framework

PART 10: Drivers and challenges

PART 11: Market trends

PART 12: Vendor landscape

PART 13: Key vendor analysis

For more information about this report visit https://www.researchandmarkets.com/research/4bqd6l/global

Contact Information:

Research and Markets,
Laura Wood,
Senior Manager.
Fax from USA: 646-607-1907
Fax from rest of the world: +353-1-481-1716
Related Topics: Infectious Diseases Drugs (https://www.researchandmarkets.com/categories.asp?cat_id=121&campaign_id=4bqd6l)

Via iCrowdNewswire
View Related News >